Morgan Stanley
CLRB icon

Morgan Stanley’s Cellectar Biosciences CLRB Stock Holding History

Morgan Stanley’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29K Hold
510
– – ﹤0.01% 7393
2025
Q4 		$1.5K Hold
510
– – ﹤0.01% 7296
2025
Q3 		$2.86K Hold
510
– – ﹤0.01% 7227
2025
Q2 		$3.63K Hold
510
– – ﹤0.01% 7113
2025
Q1 		$4.83K Sell
510
-5,447
-91% -$49.3K ﹤0.01% 7002
2024
Q4 		$53.4K Buy
5,957
+1,316
+28% +$60.8K ﹤0.01% 6265
2024
Q3 		$298K Buy
4,641
+1,860
+67% +$123K ﹤0.01% 5609
2024
Q2 		$209K Buy
2,781
+2,073
+293% +$199K ﹤0.01% 5658
2024
Q1 		$84.6K Sell
708
-296
-29% -$32.1K ﹤0.01% 6060
2023
Q4 		$83.4K Buy
1,004
+504
+101% +$37.5K ﹤0.01% 6220
2023
Q3 		$39.6K Hold
500
– – ﹤0.01% 6263
2023
Q2 		$29.3K Hold
500
– – ﹤0.01% 6424
2023
Q1 		$21.4K Hold
500
– – ﹤0.01% 6600
2022
Q4 		$25.6K Hold
500
– – ﹤0.01% 6570
2022
Q3 		$50K Buy
+500
New +$71.9K ﹤0.01% 6403
2022
Q2 		– Hold
0
– – – 7826
2022
Q1 		– Sell
-923
Closed -$162K – 7978
2021
Q4 		$184K Sell
923
-1,005
-52% -$242K ﹤0.01% 6118
2021
Q3 		$535K Buy
1,928
+1,496
+346% +$457K ﹤0.01% 5451
2021
Q2 		$155K Buy
432
+425
+6,071% +$184K ﹤0.01% 6140
2021
Q1 		$4K Hold
7
– – ﹤0.01% 7144
2020
Q4 		$5K Hold
7
– – ﹤0.01% 6762
2020
Q3 		$3K Hold
7
– – ﹤0.01% 6509
2020
Q2 		$3K Sell
7
-34
-83% -$14.3K ﹤0.01% 6382
2020
Q1 		$16K Hold
41
– – ﹤0.01% 5881
2019
Q4 		$27K Sell
41
-66
-62% -$34.3K ﹤0.01% 6027
2019
Q3 		$64K Sell
107
-10
-9% -$6.53K ﹤0.01% 5607
2019
Q2 		$77K Sell
117
-60
-34% -$40.9K ﹤0.01% 5436
2019
Q1 		$125K Sell
177
-43
-20% -$26.2K ﹤0.01% 5294
2018
Q4 		$102K Buy
220
+145
+193% +$103K ﹤0.01% 5550
2018
Q3 		$67K Buy
75
+73
+3,650% +$86K ﹤0.01% 5801
2018
Q2 		$3K Hold
2
– – ﹤0.01% 6500
2018
Q1 		$6K Hold
2
– – ﹤0.01% 6359
2017
Q4 		$7K Hold
2
– – ﹤0.01% 6279
2017
Q3 		$9K Sell
2
-1
-33% -$4.85K ﹤0.01% 6189
2017
Q2 		$16K Sell
3
-1
-25% -$5.48K ﹤0.01% 6138
2017
Q1 		$29K Sell
4
-12
-75% -$71.3K ﹤0.01% 5976
2016
Q4 		$59K Buy
16
+10
+167% +$54.2K ﹤0.01% 5705
2016
Q3 		$50K Buy
6
+3
+100% +$24.6K ﹤0.01% 5594
2016
Q2 		$29K Buy
+3
New +$25.1K ﹤0.01% 5717
2016
Q1 		– Hold
0
– – – 6586
2015
Q4 		– Hold
0
– – – 6499
2015
Q3 		– Hold
0
– – – 6372
2015
Q2 		– Hold
0
– – – 6294
2015
Q1 		– Hold
0
– – – 5911
2014
Q4 		– Hold
0
– – – 5967
2014
Q3 		– Hold
0
– – – 6295

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley's CLRB Position: Q1 2026 in Review

Morgan Stanley held its Cellectar Biosciences (CLRB) position steady in Q1 2026 at 510 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #7393.

Morgan Stanley first reported a position in CLRB in Q2 2016 and has held it in 38 quarters since. The position peaked at $535K in Q3 2021. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • Morgan Stanley held 510 shares of Cellectar Biosciences worth $1.29K as of Q1 2026.
  • Morgan Stanley left its Cellectar Biosciences share count unchanged in Q1 2026.
  • Cellectar Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7393 holding.
  • Morgan Stanley first reported a position in Cellectar Biosciences in Q2 2016 and has held it in 38 quarters since.
  • Morgan Stanley's Cellectar Biosciences position peaked at $535K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.